Exploring these pathways could clarify their specific benefits in Alport syndrome compared to other forms of CKD
This was highlighted in a recent study performed in a mouse model of obesity-induced T2DM, in which an 8-week exendin-4 treatment, starting 3 days post-stroke, improved neurological recovery by reversing T2DM-induced atrophy of parvalbumin-positive GABAergic interneurons, which play a key role in neuroplasticity [8]
Interestingly, for the UGT74F2 T15S in complex with UDP and 2-BA, the electron density for 2-BA and in particular for its carboxylate group is stronger and better defined than in the analogous complex of the wild-type protein (Supplementary Fig
some heat or tingling as well as my downtime after each treatment
Food and Drug Administration emphasizes bodycomposition monitoring and functional outcomes, reflecting the fields maturation from how much weight is lost? to what else is improving? Competitive dynamics and reimbursement pressures are already influencing trial feasibility, while treatment shortages, manufacturing scale-up and off-label demand have impacted trial operations and site engagement globally
